ChrysCapital Fund X Reaches $2.2 Billion
ChrysCapital has successfully launched Fund X with a total of $2.2 billion, representing the largest private equity fund raised by an India-focused firm. This new fund reflects a 60% increase compared to Fund IX, which closed at $1.35 billion in 2022. The firm has plans to strategically invest this capital in a variety of established sectors, including consumer, healthcare, financial services, enterprise technology, and industrial categories.
Fundraising Success and Investment Strategy
Since its inception in 1999, ChrysCapital has amassed approximately $8.5 billion through ten private equity funds, one continuation vehicle, and a public markets fund. The firm has effectively deployed more than $5.5 billion across a notable 110 portfolio companies and realised around $7.8 billion through 80 exits, boasting a reported 3.0x return on investment (ROI).
Key Investments and Portfolio
ChrysCapital’s previous investments span across respected companies such as Intas Pharmaceuticals, Mankind Pharma, GeBBS Healthcare, Infogain, NSE, and Awfis. With Fund X, the firm has successfully welcomed over 30 new global investors, including pension funds, insurers, asset managers, and family offices deriving from Japan, the Middle East, Southeast Asia, Europe, and the United States.
New Institutional Investors Join Fund X
In a noteworthy development, ChrysCapital has also garnered investment from Indian institutional investors and large family offices for the first time. The fund achieved its final close within just six months of its initial close.
Future Plans for Fund X
The firm intends to deploy the funds from Fund X across the next 3–4 years and is already in the midst of several transactions. Its investment strategy maintains a focus on both majority and minority stakes in businesses that exhibit strong governance, defined growth levers, and clear exit visibility.
Competitive Landscape
ChrysCapital operates in a competitive space alongside other private equity firms in India, such as TPG, Bain Capital, KKR, Blackstone, Carlyle, Warburg Pincus, and Multiples.